임머론 (IMRN) 주가

임머론(IMRN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.22 (+3.39%), 시가총액 $0.01B, 52주 최저~최고 $0.70 ~ $2.35.

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and

핵심 지표

• 현재가: $1.22 (+3.39%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.70 ~ $2.35
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

임머론의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

임머론 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.69
• 순이익률: -0.62%
• 영업이익률: -0.47%

자주 묻는 질문